Perrigo Gives UK Dieters A Boost With XLS-Medical
Perrigo launches new XLS-Medical Ultra 5 slimming aid just in time for the UK government's new weight-loss drive in response to the COVID-19 pandemic.
You may also be interested in...
GSK Consumer Healthcare is increasing the "positive diversity and representation of LGBTQ+ people" in a series of new marketing campaigns for Sensodyne and Voltarol in the UK.
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."